New approvals and data in vaccines should see growth return after the current headwinds have been navigated.” It comes after GSK struck a landmark 2.2 billion US dollar (£1.68 billion) settlement to ...
Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand, sending shares in the British pharmaceutical company down 3% in U.S. trading Wednesday. GSK, which had ...
GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.
Boasting a new logo and revised font, Eurostar is in the process of merging the brands. For regular travelers like this journalist, there was hope that this branding work would lead to a broader ...
Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...
It’s important to note that both Tesla and Musk specifically mentioned “this year” when trying to shut down rumors of a new Model Y. It led many to think that a refresh is coming ...
GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...
GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine production site in Pennsylvania. … ...
Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...
The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines drug substance facility and an R&D pilot plant. Pennsylvania Governor Josh ...
US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback